TERNANOMED
TERPENOYLATION: AN ORIGINAL CONCEPT FOR THE DISCOVERY OF NEW NANOMEDICINES
| Coordinatore | UNIVERSITE PARIS-SUD
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 2˙198˙799 € |
| EC contributo | 2˙198˙799 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2009-AdG |
| Funding Scheme | ERC-AG |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-06-01 - 2015-05-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
SOCIETE DE PHARMACOLOGIE ET D'IMMUNOLOGIE BIO SA
Organization address
city: Montigny le Bretonneux contact info |
FR (Montigny le Bretonneux) | beneficiary | 150˙000.00 |
| 2 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | beneficiary | 120˙000.00 |
| 3 |
UNIVERSITE CATHOLIQUE DE LOUVAIN
Organization address
address: Place De L'Universite 1 contact info |
BE (LOUVAIN LA NEUVE) | beneficiary | 12˙000.00 |
| 4 |
UNIVERSITE PARIS-SUD
Organization address
address: RUE GEORGES CLEMENCEAU 15 contact info |
FR (ORSAY) | hostInstitution | 1˙916˙799.00 |
| 5 |
UNIVERSITE PARIS-SUD
Organization address
address: RUE GEORGES CLEMENCEAU 15 contact info |
FR (ORSAY) | hostInstitution | 1˙916˙799.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Terpenoids are a group of natural compounds that are extraordinary diverse in chemistry, structure and function. Most of the natural terpenoids are flexible and biocompatible biopolymers, having physico-chemical characteristics able to adapt to a wide variety of biologically active compounds. Surprisingly, they have never been used previously in the nanotechnology field for drug delivery and targeting purposes, except very recently by us to design squalene-based nanoassemblies. Thus, the current project aims to develop terpenoid-based nanoassemblies to improve the treatment of severe diseases incl. cancer, infectious and metabolic diseases. The conceptual approach is to chemically link a terpenoid to a biologically active drug molecule in order to allow the resulting bioconjugate to self-assemble as nanoparticles in water. Noteworthy, the nature of the polyterpenoid (ie. number of isoprenoid units) may be adapted to the hydrophilic/lipophilic character of the drug molecule to be transported, whereas the nature of the linkage (ester, amide, disulfide bonds etc.) will be selected according to the enzymatic content of the targeted diseased area. From the ratio between drug s and polyterpene s molecular weights, it is deduced that the drug loading will be dramatically improved as compared to the currently available nanomedicines. In other words, the pro-drug will form the nanomedicine by selfaggregation without the need of any other transporter material. The project will involve the following interdisciplinary aspects:(i) synthesis of drug/polyterpene bioconjugates,(ii)design of the nanoassemblies and their functionalization with recognition ligands,(iii)cell and tissue imaging and(iv)pharmacological evaluation in vitro (cell culture) and in vivo. Such ambitious and challenging project will be performed under Patrick Couvreur s leadership who has settled up a worldwide recognized multidisciplinary research team, unique in the nanomedicine world.'